

ZymiQ secures Japanese patent for enzyme-based anti-biofilm technology

ZymiQ Technology AB today announced a granted patent in Japan covering its proprietary enzyme-based technology for the prevention and degradation of microbial biofilms. The grant marks a significant milestone in the company's global IP strategy.

Biofilms are a major underlying factor in chronic infections, antimicrobial resistance (AMR), and oral diseases such as gingivitis and periodontitis. By directly targeting biofilm structures, ZymiQ's technology introduces a fundamentally different approach to conventional antimicrobial treatments.

The Japanese patent builds on an expanding international IP portfolio, including a granted European patent with Unitary Patent coverage, validation in the United Kingdom, and protection in Hong Kong. Additional applications are progressing in multiple jurisdictions worldwide.

The technology enables both prevention of biofilm formation and active degradation of existing microbial deposits. Stabilized for use under physiological conditions, it is adaptable across sprays, gels, and oral care formats, supporting commercialization across medical and consumer health markets.

Japan is a strategically important future market for ZymiQ, given its leadership in healthcare innovation and oral care. Patent protection in the region strengthens the company's ability to pursue partnerships, licensing agreements, and market entry across Asia.

ZymiQ's platform underpins a growing pipeline targeting oral health, dermatology, wound care, and veterinary applications.

"Japan is a future key market for us, and this patent is another step in building the IP foundation our platform deserves," said Michael Edelborg Christensen, CEO of ZymiQ Technology. "Enzyme-based solutions will become the new standard in managing biofilm-driven infections globally."

For more information, please contact:

Michael Edelborg Christensen, CEO

Phone +46 727 144 166

Email: michael.christensen@zymiq.com

About ZymiQ

ZymiQ Technology AB (publ) is a life science company headquartered in Lund, Sweden and the parent company of the ZymiQ Group. Subsidiaries include ZymiQ Biopharma AB, Sweden and ZymiQ Animal Health LLC, Virginia, USA. The company is also represented by offices in Singapore and Malaysia. ZymiQ develops, manufactures and sells innovative enzyme-based therapeutic and cosmetic products for the well-being of humans and animals. ZymiQ also conducts pioneering research on future alternatives to antibiotics to combat the global challenge of antibiotic resistance, www.zymiq.com

Attachments

[ZymiQ secures Japanese patent for enzyme-based anti-biofilm technology](#)